VIVOS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VIVOS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $5.0K | Mar 24, 2025 |
| FY2018 | Dec 31, 2017 | $4.1K | Mar 25, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.4K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $28.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $19.5K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $36.5K | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $14.9K | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $7.0K | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $9.5K | Mar 24, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($59.8K) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($3.0K) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($6.0K) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $7.7K | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $2.9K | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.4K | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $3.5K | Mar 24, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.07M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.91M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($2.89M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($2.47M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($2.53M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($957.0K) | Mar 7, 2022 |
| FY2019 | Dec 31, 2019 | ($504.0K) | Apr 28, 2020 |
| FY2019 | Sep 30, 2019 | ($669.4K) | Apr 28, 2020 |
| FY2019 | Jun 30, 2019 | ($200.3K) | Apr 28, 2020 |
| FY2019 | Mar 31, 2019 | ($236.4K) | Apr 28, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.17M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.60M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($2.79M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($2.52M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($2.50M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($672.5K) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($1.33M) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($2.49M) | Apr 28, 2020 |
| FY2018 | Dec 31, 2017 | ($2.62M) | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | ($4.44M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $352.2K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $324.6K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $732.7K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $343.8K | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $286.8K | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $84.7K | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $67.6K | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $104.2K | Apr 28, 2020 |
| FY2018 | Dec 31, 2017 | $203.0K | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | $328.0K | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.06M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($1.68M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($1.29M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($1.12M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($963.8K) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($875.8K) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($837.1K) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($700.5K) | Apr 28, 2020 |
| FY2018 | Dec 31, 2017 | ($1.29M) | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | ($1.93M) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.2K | Mar 31, 2026 |
| FY2013 | Dec 31, 2013 | $0 | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | $14.8K | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $0 | Mar 29, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.87M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.23M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.61M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.74M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $1.63M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $937.5K | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $43.9K | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $16.5K | Apr 28, 2020 |
| FY2018 | Dec 31, 2017 | $15.7K | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | $42.0K | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $206.7K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $86.2K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $245.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $81.7K | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $166.9K | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $905.5K | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $1.52M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $958.7K | Apr 28, 2020 |
| FY2018 | Dec 31, 2017 | $4.28M | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | $3.06M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.66M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.15M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $1.37M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $1.66M | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | $1.47M | Mar 18, 2024 |
| FY2022 | Dec 31, 2020 | $32.0K | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($1.48M) | Mar 7, 2022 |
| FY2019 | Sep 30, 2019 | ($1.19M) | Apr 28, 2020 |
| FY2019 | Jun 30, 2019 | ($1.23M) | Apr 28, 2020 |
| FY2019 | Mar 31, 2019 | ($1.05M) | Apr 28, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($88.43M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($85.36M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($82.45M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($79.56M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($77.09M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | ($74.56M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($73.60M) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($71.99M) | Apr 28, 2020 |
| FY2018 | Dec 31, 2017 | ($64.29M) | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | ($57.87M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.21M | Mar 24, 2025 |
| FY2023 | Dec 31, 2023 | $1.59M | Mar 18, 2024 |
| FY2022 | Dec 31, 2022 | $1.71M | Mar 1, 2023 |
| FY2022 | Dec 31, 2021 | $1.61M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $903.7K | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $20.4K | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $5.5K | Apr 28, 2020 |
| FY2017 | Dec 31, 2017 | $8.3K | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $27.9K | Apr 2, 2018 |
| FY2017 | Dec 31, 2015 | $179.0K | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 1, 2023 |
| FY2014 | Dec 31, 2014 | 0 | Apr 21, 2015 |
| FY2014 | Dec 31, 2013 | 0 | Apr 21, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | 0 | Mar 29, 2013 |
| FY2011 | Dec 31, 2010 | 0 | Mar 23, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 18, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 455.49M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 440.87M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 387.89M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 362.54M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | 343.53M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 292.28M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | 184.85M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | 163.45M | Apr 28, 2020 |
| FY2018 | Dec 31, 2017 | 65.70M | Mar 25, 2019 |
| FY2017 | Dec 31, 2016 | 31.74M | Apr 2, 2018 |